TABLE 2.
Summary of primary outcomes of included studies
| Study | Intervention | Brain injury (cull time point post‐injury) | Motor function outcomes (time point/s post‐injury) | Cognitive function outcomes (time point/s post‐injury) |
|---|---|---|---|---|
| Braccioli 2017 28 | NSCs | Infarct size: reduced 56 d | Cylinder test: improved 28, 56 d | |
| Braccioli 2017 29 | NSCs | Cylinder test: improved 28 d | ||
| NSCs FOXP1 KO | Cylinder test: NS | |||
| Chau 2014 30 | NPCs | Forelimb placement test: NS | ||
| Comi 2008 31 | NSCs after 2 d | Infarct size: reduced 28 d | ||
| NSCs after 7 d | Infarct size: NS | |||
| Daadi 2010 32 | NSCs | Infarct size: NS |
Cylinder test: improved 28, 31 d Rotarod test: improved 30, 32 d |
|
| Ji 2015 33 | NSCs | Infarct size: reduced 43 d |
Gait test: improved 6 d Grid walking test: improved 8 d |
Morris water maze: improved 33 d Social choice test: improved 29 d |
| Kim 2018 34 | OPCs single dose |
Cylinder test: improved 23 d Rotarod test: improved 7, 13, 23, 33 d Open field test: improved 13, 23, 33 d |
Morris water maze: improved 30 d Passive avoidance test: improved 38 d |
|
| OPCs repeated doses |
Cylinder test: improved 23 d Rotarod test: improved 13, 23, 33 d Open field test: improved 13, 23, 33 d |
Morris water maze: improved 30 d Passive avoidance test: improved 38 d |
||
| Li 2015 35 | NSCs | Morris water maze: improved 29 d | ||
| Rumajogee 2018 36 | NPCs | Hemisphere size: NS |
Cylinder test: improved 42, 49, 56, 63, 77 d Cat walk test: improved 21, 28, 35, 42, 49, 56, 63, 77 d |
|
| Sato 2008 37 | NSPCs | Hemisphere size: NS | ||
| NSPCs + chABC | Hemisphere size: reduced 9 d | |||
| Shin 2018 38 | NPCs | Infarct size: NS | Rotarod test: NS | |
| NPCs + scaffold | Infarct size: reduced 63 d | Rotarod test: improved 84 d | ||
| Shinoyama 2013 39 | NPCs |
Rotarod test: improved 23 d Beam walking test: improved 23 d |
||
| Tan 2014 40 | NSCs | Holding test: improved 23 d | Radial arm test: improved 23 d | |
| NSCs + VEGF | Holding test: improved 23 d | Radial arm test: improved 23 d | ||
| Titomanlio 2011 41 | NDPs after 4 h | Gray and white matter infarct size: reduced 5 d | Open field: NS | Novel object recognition test: improved 16, 35 d |
| NDPs after 72 h | Open field: NS | Novel object recognition test: improved 16 d | ||
| Wang 2014 42 | NSCs | Infarct size: NS |
Cylinder test: NS Rotarod test: NS |
Morris water maze: NS |
| NSCs + hypothermia | Infarct size: reduced 7, 14, 28 d |
Cylinder test: NS Rotarod test: improved 22, 29, 36 d |
Morris water maze: improved 57, 169 d | |
| Yao 2016 43 | NSCs | Attitudinal reflex test: improved 27 d | Radial arm test: improved 27 d | |
| NSCs + VEGF | Attitudinal reflex test: improved 27 d | Radial arm test: improved 27 d | ||
| Ye 2018 44 | NSCs | MAP‐2 volume loss: reduced 35 d |
Cylinder test: improved 21, 28, 35 d Adhesive removal test: improved 35 d |
|
| NSCs + bFGF | MAP‐2 volume loss: reduced 35 d |
Cylinder test: improved 21, 28, 35 d Adhesive removal test: improved 35 d |
||
| Zheng 2012 45 | NSCs | Foot fault test: improved 17 d | T test: improved 17 d | |
| NSCs + VEGF | Foot fault test: improved 17 d | T test: improved 17 d |
Note: Empty cells = did not measure this outcome, improved/reduced = significant improvement or reduction following NSC treatment, compared with the injured control (P < .05).
Abbreviations: bFGF, basic fibroblast growth factor; chABC, chondroitinase ABC; FOXP1, Forkhead Box P1; KO, knockout; MAP‐2, microtubule‐associated protein 2; NDPs, neurosphere derived precursor cells; NPCs, neural progenitor cells; NS, not significant; NSCs, neural stem cells; NSPCs, neural stem progenitor cells; OPCs, oligodendrocyte progenitor cells; VEGF, vascular endothelial growth fact.